In today’s fast-paced, innovation-fueled biopharma landscape, the traditional model of C-suite leadership is being turned on ...

One of the goals of the current administration is to implement the use of AI in FDA’s approval process. Proponents of the ...

The Medipost CEO discusses developing treatments for knee osteoarthritis and other conditions.

Edward Ahn, CEO of MEDIPOST, Inc., reacts to the challenge of launching orphan drugs without complete evidence, particularly given their high cost and limited patient populations, and suggests ...

The supplemental New Drug Application is supported by Phase III data, which showed Caplyta significantly prolonged time to ...